Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP).
2016
5071Background: Management of HRPCa remains a clinical challenge. Novel AR inhibitors are now standard of care in castration-resistant prostate cancer (CRPC) and could potentially impact outcome in...
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI